Figure 4.

Concordance of exosome‐derived CYP3A4 biomarkers and midazolam CL/F in a cohort of healthy males (n = 6). (A) Exosome‐derived CYP3A4 protein expression vs. midazolam CL/F. (B) Exosome‐derived CYP3A4 mRNA expression vs. midazolam CL/F. (C) Ex vivo CYP3A4 activity (rate of 1‐hydroxymidazolam formation) vs. midazolam CL/F. (D) Exosome‐derived CYP3A4 mRNA expression vs. exosome‐derived CYP3A4 protein expression. (E) Ex vivo CYP3A4 activity vs. exosome‐derived CYP3A4 protein expression. (F) Ex vivo CYP3A4 activity vs. exosome‐derived CYP3A4 protein expression